Pfizer News - June 2026

🟢 PFE is trading 2.5% up today after FDA expands IBRANCE breast cancer indication

PFE is trading 2.5% up at $24.27 after the FDA approved an expanded indication for its breast cancer drug, IBRANCE. • The June 24, 2026, decision allows...

Pfizer pauses major acquisitions for AI efficiency, targeting stock recovery

Pfizer is pausing large-scale acquisitions to prioritize operational transformation through artificial intelligence. This shift follows the $43 billion...